SNWV — SANUWAVE Health Inc.

Summary of SANUWAVE (SNWV) Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $13.4 million, a 30% increase year-over-year.
• Full Year Revenue: $44.1 million, up 35% from 2024.
• Adjusted EBITDA: $4.8 million in Q4, up from $3.7 million in Q4 2024; full-year adjusted EBITDA rose to $13.6 million, an 89% increase.
• Gross Margin: 74.7% for Q4, down 320 basis points year-over-year due to a $486,000 inventory write-off related to discontinued products.
• Net Income: $7.7 million in Q4, a significant improvement from a net loss of $13.3 million in Q4 2024, primarily due to a noncash gain from derivative liabilities.
• Active Systems Count: 1,292 at the end of Q4, a 5% increase from Q3, despite 168 systems being discontinued.

2. Strategic Updates and Business Highlights

• UltraMIST Systems: Sold 255 systems in Q4, a record for the company, with a total of 624 systems sold in 2025.
• Reseller Partnerships: Increased focus on engaging resellers and distributors, with 32% of Q4 revenues coming from these channels, up from 26% in the prior quarter.
• Product Line Changes: Discontinued the dermaPACE and Profile product lines, which contributed to increased costs in Q4.
• Market Adaptation: The company is adapting to changes in the wound care market, particularly related to CMS reimbursement policies, and is seeing new customer segments emerge.

3. Forward Guidance and Outlook

• Q1 2026 Revenue Guidance: Expected to be between $9.6 million and $10.3 million, reflecting a 3% to 10% increase year-over-year.
• Full-Year 2026 Revenue Growth: Preliminary guidance suggests a growth range of 16% to 25% compared to 2025, with expectations for improvement in the latter half of the year.
• Sales Cycle: Anticipated to be extended due to recent industry disruptions but showing signs of recovery.

4. Bad News, Challenges, or Points of Concern

• Reimbursement Pressures: Significant reductions in CMS reimbursement rates for skin substitutes have created challenges for customers, leading to increased audits and financial distress in the wound care sector.
• Customer Base Impact: The changes have led to a decline in customer and patient counts for some clients, affecting SANUWAVE's growth rate.
• Discontinued Systems: The high number of discontinued systems (168) in Q4 reflects the financial struggles faced by some customers, raising concerns about the stability of the customer base.
• Sales Cycle Lengthening: The selling cycle has been stretched due to uncertainty in the market, particularly among larger healthcare providers.

5. Notable Q&A Insights

• Sales Cycle Dynamics: The CEO noted that smaller practitioners tend to buy more quickly, while larger institutions may take longer to finalize purchases.
• Reseller Relationships: The company is focusing on larger resellers with significant personnel, which could enhance sales potential but also requires time for ramp-up.
• R&D and New Products: There is ongoing investment in R&D, with potential new product developments being explored, though details will be shared in future calls.
• Market Education: There is a significant educational component in selling UltraMIST, as many potential customers are still grappling with the implications of recent reimbursement changes.

Overall, SANUWAVE reported strong financial results for Q4 2025 but faces significant challenges due to changes in the reimbursement landscape and its impact on customers. The company is adapting its strategy to leverage new opportunities while navigating these headwinds.